Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Absorption of Avastin and Lucentis in Diabetic Macular Edema
NCT01661946Phase 3Completed
- Sponsor
- Queen's University
- Start
- Aug 2012
- Primary completion
- Jul 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetic macular edema (DME) comparing Ranibizumab with Bevacizumab (2 arms). Primary endpoint: Maximum Concentration of Anti-VEGF Antibody at 1 month. Started Aug 2012; status: completed.
02
Drugs
bevacizumabranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01661946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661946.